Literature DB >> 25034196

Administrative data on diagnosis and mineralocorticoid receptor antagonist prescription identified patients with primary aldosteronism in Taiwan.

Vin-Cent Wu1, Ya-Hui Hu2, Che-Hsiung Wu3, Chih-Chin Kao4, Cheng-Yi Wang5, Wei-Shen Yang6, Hsiu-Hao Lee7, Yuan-Shian Chang8, Yen-Hung Lin1, Shuo-Meng Wang9, Likwang Chen10, Kwan-Dun Wu1.   

Abstract

OBJECTIVES: To develop algorithms of locating patients with primary aldosteronism (PA) using insurance reimbursement data and to validate the algorithms using medical charts. STUDY DESIGN AND
SETTING: We extracted National Health Insurance (NHI) reimbursement data and medical charts in seven enrolled hospitals and analyzed diagnosis-related information for 1999-2010. The NHI codes PA as 255.1x, using the International Classification of Diseases, Ninth Revision, Clinical Modification. Confirmation of PA was based on suppression tests.
RESULTS: We reviewed medical charts for 1,094 cases with at least one PA diagnosis. PA was confirmed for 563 cases. Compared with patients with essential hypertension, PA patients had higher systolic blood pressure, higher aldosterone, lower renin activity, and lower potassium level (all P-values <0.05). An algorithm based on PA diagnosis reported in at least one hospital stay or three outpatient visits had modest performance (sensitivity = 0.94 and specificity = 0.20). The best additional condition for the algorithm was use of mineralocorticoid receptor antagonist (MRA; sensitivity = 0.89 and specificity = 0.88).
CONCLUSION: Using information on PA diagnosis and MRA prescription reported in insurance claims data can precisely locate PA patients in high-risk groups. This algorithm can construct a reliable PA sample for conducting research in various fields, including epidemiology and clinical practice.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adjudication; Administrative data; Medical chart review; Mineralocorticoid receptor antagonist; Primary aldosteronism; Validation

Mesh:

Substances:

Year:  2014        PMID: 25034196     DOI: 10.1016/j.jclinepi.2014.05.012

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  25 in total

1.  Insomnia and the Risk of Atrial Fibrillation: A Population-Based Cohort Study.

Authors:  Hsiu-Hao Lee; Yueh-Chung Chen; Jien-Jiun Chen; Shih-Hsiang Lo; Yue-Liang Guo; Hsiao-Yun Hu
Journal:  Acta Cardiol Sin       Date:  2017-03       Impact factor: 2.672

2.  A Novel Somatic Mutation of CACNA1H p.V1937M in Unilateral Primary Hyperaldosteronism.

Authors:  Chi-Shin Tseng; Kang-Yung Peng; Shuo-Meng Wang; Yao-Chou Tsai; Kuo-How Huang; Wei-Chou Lin; Ya-Hui Hu; Vin-Cent Wu; Jeff S Chueh
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

3.  The impact of acute kidney injury on the long-term risk of stroke.

Authors:  Vin-Cent Wu; Pei-Chen Wu; Che-Hsiung Wu; Tao-Min Huang; Chia-Hsuin Chang; Pi-Ru Tsai; Wen-Je Ko; Likwang Chen; Cheng-Yi Wang; Tzong-Shinn Chu; Kwan-Dun Wu
Journal:  J Am Heart Assoc       Date:  2014-07-15       Impact factor: 5.501

4.  The secular trends in the incidence rate and outcomes of out-of-hospital cardiac arrest in Taiwan--a nationwide population-based study.

Authors:  Cheng-Yi Wang; Jen-Yu Wang; Nai-Chi Teng; Ting-Ting Chao; Shu-Ling Tsai; Chi-Liang Chen; Jeng-Yuan Hsu; Chin-Pyng Wu; Chih-Cheng Lai; Likwang Chen
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

5.  Risk of liver injury after α-glucosidase inhibitor therapy in advanced chronic kidney disease patients.

Authors:  Chih-Chin Kao; Pei-Chen Wu; Che-Hsiung Wu; Li-kwang Chen; Hsi-Hsien Chen; Mai-Szu Wu; Vin-Cent Wu
Journal:  Sci Rep       Date:  2016-01-11       Impact factor: 4.379

6.  Long term outcome of Aldosteronism after target treatments.

Authors:  Vin-Cent Wu; Shuo-Meng Wang; Chia-Hui Chang; Ya-Hui Hu; Lian-Yu Lin; Yen-Hung Lin; Shih-Chieh Jeff Chueh; Likwang Chen; Kwan-Dun Wu
Journal:  Sci Rep       Date:  2016-09-02       Impact factor: 4.379

7.  Comparative Study of Outcomes among Patients with Polycystic Kidney Disease on Hemodialysis and Peritoneal Dialysis.

Authors:  Ju-Yeh Yang; Likwang Chen; Chia-Ter Chao; Yu-Sen Peng; Chih-Kang Chiang; Tze-Wah Kao; Kuo-Liong Chien; Hon-Yen Wu; Jenq-Wen Huang; Kuan-Yu Hung
Journal:  Sci Rep       Date:  2015-08-06       Impact factor: 4.379

8.  High Risk of Herpes Zoster among Patients with Advance Acute Kidney Injury--A Population-Based Study.

Authors:  Wei-Shun Yang; Fu-Chang Hu; Meng-Kan Chen; Wen-Je Ko; Likwang Chen; Kwan-Dun Wu; Vin-Cent Wu
Journal:  Sci Rep       Date:  2015-09-03       Impact factor: 4.379

9.  Time course and factors predicting arterial stiffness reversal in patients with aldosterone-producing adenoma after adrenalectomy: prospective study of 102 patients.

Authors:  Che-Wei Liao; Lian-Yu Lin; Chi-Sheng Hung; Yen-Tin Lin; Yi-Yao Chang; Shuo-Meng Wang; Vin-Cent Wu; Kwan-Dun Wu; Yi-Lwun Ho; Fumitoshi Satoh; Yen-Hung Lin
Journal:  Sci Rep       Date:  2016-02-17       Impact factor: 4.379

10.  Outcome Comparisons Between Patients on Peritoneal Dialysis With and Without Polycystic Kidney Disease: A Nationwide Matched Cohort Study.

Authors:  Ju-Yeh Yang; Likwang Chen; Chia-Ter Chao; Yu-Sen Peng; Chih-Kang Chiang; Tze-Wah Kao; Kuo-Liong Chien; Hon-Yen Wu; Jenq-Wen Huang; Kuan-Yu Hung
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.